

# 1 **Multiplex ACE2-RBD Binding Inhibition Assay: An Integrated Tool for** 2 **Assessing Neutralizing Antibodies to SARS-CoV-2 Variants and** 3 **Protection against Breakthrough Infections**

4 Emma Bloch<sup>1</sup>, Laura Garcia<sup>1</sup>, Françoise Donnadieu<sup>1</sup>, Jason Rosado<sup>1</sup>, Delphine Planas<sup>2</sup>, Timothée Bruel<sup>2</sup>,  
5 Laurent Hocqueloux<sup>3,4</sup>, Thierry Prazuck<sup>3,4</sup>, Olivier Schwartz<sup>2</sup>, Laura Tondeur<sup>5</sup>, Laurie Pinaud<sup>5</sup>, Arnaud  
6 Fontanet<sup>5,6</sup>, Stéphane Pelleau<sup>1</sup>, Michael White<sup>1</sup>

- 7 1. Infectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France
- 8 2. Virus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.
- 9 3. Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Régional, Orléans, France.
- 10 4. IPIC, Laboratoire Interdisciplinaire pour l'Innovation et la Recherche en Santé d'Orléans (LFRSO),  
11 Université d'Orléans, Orléans, France.
- 12 5. Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
- 13 6. PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.

## 16 **Correspondence**

17 Dr Michael White, [michael.white@pasteur.fr](mailto:michael.white@pasteur.fr)

## 19 **Abstract**

20 SARS-CoV-2 remains a significant health threat due to its high infection and mutation rates. The emergence of  
21 new variants of concern poses challenges as they can lead to immune escape mutations, potentially reducing the  
22 efficacy of vaccines and antibody therapeutics. The receptor binding domain (RBD) of SARS-CoV-2 is  
23 particularly noteworthy as it is both the most rapidly evolving domain and the principal target of neutralizing  
24 antibodies. As an alternative to time-consuming and expensive neutralization assays, we have developed a bead-  
25 based multiplex surrogate virus neutralization test based on ACE2-RBD binding inhibition. We demonstrated  
26 how our high-throughput assay allows us to simultaneously assess anti-RBD neutralizing antibodies levels  
27 against multiple SARS-CoV-2 variants, providing data that is consistent with the gold-standard live virus  
28 neutralization assay. The utility of this assay was demonstrated by applying it to a large French population  
29 cohort to demonstrate that hybrid immunity (generated by a combination of vaccination and infection) is  
30 associated with protection against infection with the Omicron BA.1 and BA.2 lineages of SARS-COV-2.

31

## 32 **Introduction**

33 SARS-CoV-2 is an enveloped RNA virus with surface projections that give rise to its corona appearance. Its  
34 genome encodes four structural proteins: spike (S), nucleocapsid (N), membrane (M), and envelope (E)<sup>1</sup>. The S  
35 and N proteins are highly immunogenic, eliciting a rapid immune response. The S glycoprotein is composed of  
36 two subunits, which form a trimeric structure on the virus surface. Subunit one (S1) harbors the receptor binding  
37 domain (RBD) of the virus, which binds to the angiotensin-converting enzyme-2 (ACE2) receptor on the host  
38 cell surface. Subunit two (S2) enables the fusion of the viral envelope with the host cellular membrane.

39 SARS-CoV-2 enters the organism mainly through the nasopharyngeal and oropharyngeal tracts of the host, via  
40 the cellular angiotensin-converting-enzyme-2 (ACE2) receptor. Cell entry also requires the presence of the  
41 transmembrane protease serine 2 (TMPRSS2) which cleaves the S protein and thus enables the membrane fusion  
42 and internalization<sup>2</sup>. The receptor involved in the cell entry plays a crucial role in determining the viral tropism  
43 and influences the severity of infection<sup>3</sup>. Primary infection or vaccine immunization leads to immune memory,  
44 providing protective immunity against subsequent infections. Various types of immunoglobulins targeting  
45 SARS-CoV-2 proteins are produced at different stages post-infection<sup>4</sup>. However, the concentration of these  
46 immunoglobulins varies significantly among individuals and over time, influenced by factors such as isotype,  
47 targeted antigen, and previous infection or vaccination history<sup>5</sup>.

48 Neutralizing antibodies interfere with the cell entry mechanism primarily by blocking the interaction of the  
49 RBD with the human cell receptor ACE2<sup>6</sup>. Anti-RBD antibodies account for approximately 90% of the  
50 neutralizing activity<sup>7</sup>. Several studies have demonstrated that the neutralizing antibody response to SARS-CoV-  
51 2 provides a correlate of protection<sup>8,9</sup>. Therefore, understanding the longevity and kinetics of the neutralizing  
52 antibody response is crucial as it has significant implications for immune protection and for the development of  
53 effective vaccination strategies.

54 Since the virus's emergence, thousands of cumulative mutations have occurred, primarily within the S protein  
55 followed by the N protein, while the M and E proteins show a lower mutation rate in the SARS-CoV-2 genome<sup>10</sup>.  
56 These mutations can lead to evolutionary advantages, such as immune escape, higher transmission rate, varying  
57 severity of infection, and impact on the performance of diagnostic tools (i.e., antigenic tests), vaccines and  
58 therapeutic medicines. The World Health Organization (WHO) has been monitoring SARS-CoV-2 evolution  
59 since January 2020, categorizing variants into variants of interest (VOIs) and variants of concern (VOCs).  
60 VOCs, including Alpha (B.1.1.7.), Beta (B.1.351), Gamma (P.1), Delta (P.1.617.2), and Omicron (multiple  
61 lineages), are linked to increased transmissibility, virulence, or reduced effectiveness of public health measures.  
62 The study and monitoring of emerging virus strains is especially important for vaccine development strategies,  
63 since first-generation vaccines elicited an immune response against the original Wuhan-Hu-1 isolate (wild-  
64 type).

65 The gold standard method to measure the neutralization capacity of antibodies remains the live virus  
66 neutralization assay, a method based on living viruses and cell culture, which is time-consuming, does not allow  
67 the multiplexing of several variants, and requires a level 3 biosafety laboratory. Additionally, highly trained  
68 operators and biosafety containment are required. Several alternative methods have been explored, including  
69 pseudo-based virus neutralization assays, ELISA-based assays, and surrogate virus neutralization assays. To  
70 better understand the neutralizing antibody response to SARS-CoV-2 in large population studies, we developed  
71 a multiplex surrogate virus neutralization assay. This assay mimics the virus-host interaction in vitro, based on  
72 the interaction between the SARS-CoV-2 RBD and ACE2<sup>11,12</sup>. The assay will assess the functional inhibition  
73 of the ACE2-RBD binding, enabling us to predict protection to a breakthrough infection and vaccine  
74 effectiveness at population level.

75

## 76 **Material and Methods**

### 77 *Patient cohort and Sample collection*

#### 78 *Longitudinal cohort - COVID-Oise study*

79 From May 2020 to May 2022, 900 individuals from the town of Crépy-en-Valois in the Oise Department in  
80 France were surveyed. In winter 2020, scientists at Institut Pasteur initiated a longitudinal cohort study, named  
81 the COVID-Oise cohort<sup>13,14</sup>. Participants comprised a wide age range (5–101 years), ranging from children to  
82 nursing home residents. The inclusion criteria were to live, work and/or study in the town of Crépy-en-Valois  
83 (ca. 15,000 inhabitants) at the time of study initiation. No exclusion criteria were applied. Participants were  
84 invited four times for collection of epidemiological data and serum samples. Data and samples from sessions  
85 held in November 2020 (Session 1), April 2021 (Session 2), November 2021 (Session 3) and May 2022 (Session  
86 4) were used in this analysis. The cohort included men and women of all ages both uninfected and infected with  
87 SARS-CoV-2, as well as some vaccinated individuals (1 doses up to 4 doses).

#### 88 *Convalescent and vaccinated individuals - Orléans cohort*

89 A longitudinal clinical study was conducted in Orléans (France), enrolling 170 individuals who had PCR-  
90 confirmed SARS-CoV-2 infection with varying levels of disease severity. Additionally, blood samples were  
91 collected from 30 healthy individuals as negative controls. The study aimed to describe the persistence of  
92 specific and neutralizing antibodies over a 24-month period starting from August 2020. At enrollment, written  
93 informed consent was collected and participants completed a questionnaire covering sociodemographic  
94 characteristics, virological findings (SARS-CoV-2 RT-qPCR results), clinical data (date of symptom onset,  
95 type of symptoms, hospitalization) and data related to anti-SARS-CoV-2 vaccination if applicable (vaccine  
96 brand, date of each vaccination dose). Serological status of participants was assessed every 3 months<sup>15</sup>.

97 A subset of individuals who underwent anti-SARS-CoV-2 vaccination had weekly blood sampling after the first  
98 dose of vaccine for a period of 52 weeks post vaccination. Samples were collected weekly for the first 6 weeks,  
99 then once every two weeks from week 6 to 24, then every month until week 52. These 12 individuals received  
100 a first dose of vaccine at week 0, a second dose at week 4 and a third booster dose at between week 24 and 32.  
101 These samples include men and women of all ages, some of whom got infected with SARS-CoV-2 Delta or  
102 Omicron variant (lineages BA.1 or BA.2). A total of 253 sera samples were collected.

### 103 Antigens – Recombinant proteins

104 A panel of 13 SARS-CoV-2 antigens have been used for the development of these multiplex surrogate  
105 neutralization tests, including Spike and RBD proteins from the ancestral virus (WT) and variants of concern  
106 (Alpha, Beta, Gamma, Delta and Omicron). Additionally, the RBD protein from the variant of interest, Kappa,  
107 has been included. Furthermore, during the preliminary phase of development, tests were conducted using  
108 SARS-CoV-2 N and M-E fusion proteins, as well as the spike (S) proteins from seasonal coronaviruses,  
109 including HCoV-NL63, HCoV-OC43, HCoV-229E, and HCoV-HKU1. The proteins used were either  
110 purchased from a Native Antigen (Oxford, UK) or produced at Institut Pasteur (Paris, France).

### 111 Coupling antigens on beads

112 We used  $1.25 \times 10^6$  Luminex® magnetic beads to prepare 500 $\mu$ L of antigen coupled beads. Beads were vortexed  
113 and sonicated prior to being transferred to a 1.5mL microcentrifuge tube. A magnetic rack was used to remove  
114 the supernatant before washing the beads with Milli-Q water. Then, the beads were activated using 0.1M sodium  
115 phosphate (NaP) pH 6.2, 10 mg/mL of EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide  
116 hydrochloride) and 10 mg/mL sulfo-NHS (sulfo N-hydroxysulfosuccinimide), they were incubated on a rotor  
117 in the dark for 20 min, at room temperature. This activation step allows the coupling of antigens to magnetic  
118 beads, through a covalent bond formed between a stable ester on the surface of the bead and the primary amine  
119 of the antigen. Thereafter, a magnetic rack was used to remove the supernatant before the beads were washed  
120 twice with PBS 1X (Phosphate-buffered saline). The mass of proteins coupled onto the beads was optimized  
121 previously, it was tested using a pool of 27 serum from RT-qPCR-confirmed SARS-CoV-2 patients and  
122 validated by generating a log-linear standard curve. Antigens were coupled to beads to their optimum  
123 concentration. The beads and antigens were incubated in a PBS 1X buffer on a rotor in the dark for 2 hours, at  
124 room temperature. Finally, the antigen coupled beads were washed three times with PBS-TBN (PBS, 1% BSA,  
125 0.02% sodium azide and 0.05% Tween-20) and stored (using the same PBS-TBN buffer) at 4 °C.

### 126 Serological assay

127 A previously described 30-plex bead-based assay was used for simultaneous detection of IgG antibodies to 16  
128 SARS-CoV-2 antigens (i.e., S proteins, RBD proteins, N protein, ME fusion protein), seasonal coronaviruses  
129 (i.e., Spike and NP proteins of HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1) and other antigens  
130 related to vaccine-preventable disease (i.e., Measles, Mumps, rubella)<sup>16</sup>. For this study purpose, we used the

131 data generated previously for anti-NP, anti-Spike WT, anti-RBD for all variants (WT, Alpha, Beta, Gamma,  
132 Delta and Omicron) IgG antibodies. The protocol used was previously described<sup>17</sup>. Plates were read using a  
133 Luminex® MAGPIX® system and the median fluorescence intensity (MFI) was measured. On each assay plate,  
134 a blank (only with beads no serum) was included to control for background signal, as well as a standard curve  
135 prepared from two-fold serial dilutions (1/50 to 1/102,400) of a pool of 27 serum from RT-qPCR-confirmed  
136 SARS-CoV-2 patients. A 5-parameter logistic curve was used to convert MFI to relative antibody unit (RAU),  
137 relative to the standard curve performed on the same plate to account for inter-assay variations.

### 138 Surrogate neutralization test based on the ACE2-RBD binding inhibition

139 To better understand the neutralizing antibody responses to SARS-CoV-2, we developed a multiplex surrogate  
140 virus neutralization test based on the functional inhibition of ACE2-RBD binding. In preliminary tests, the  
141 optimum ACE2, serum, and Streptavidin-Phycoerythrin concentration were selected. Subsequently, we have  
142 evaluated which SARS-CoV-2 antigens are capable of binding to ACE2. Antigens such as the M-E protein, S2  
143 protein or N protein were excluded by their inability to bind to ACE2. Additionally, we study the possible cross-  
144 reactivity between various seasonal coronavirus S proteins (i.e., HCoV-NL63, HCoV-OC43, HCoV-229E and  
145 HCoV-HKU1). After analysis, we observed the ACE2 protein is unable to recognize and bind to seasonal  
146 coronavirus S protein. Lastly, the potential impact of multiplexing was assessed by testing each antigen-coupled  
147 bead individually and in a multiplex setting. No discernible interactions were observed among the different  
148 antigen-coupled beads during multiplexing. This trial enabled a transition from monoplex to multiplex.

149 Following assay optimization, an 8-plex bead-based assay including Spike and RBD proteins from the ancestral  
150 virus (WT) and RBD protein from variants of concern: Alpha, Beta, Gamma, Delta and Omicron (lineage BA.1)  
151 and variant of interest: Kappa was performed. In brief, 20 µl of soluble biotinylated ACE2 (from Sino  
152 Biological) at 1µg/mL, 10 µl of diluted serum (1/200 final dilution) and 20 µl of the 13 plex antigen-coupled  
153 beads premix are mixed. Following a 30-minute incubation on a shaker in the dark at room temperature, three  
154 wash steps were performed on a plate magnet using PBT. Subsequently, 40 µl of R-Phycoerythrin conjugated  
155 Streptavidin (from Jackson ImmunoResearch) at 4 µg/mL was added into each well, and the plate was incubated  
156 on a shaker in the dark for 15 min, at room temperature. Lastly, three PBT washes were performed on a magnet  
157 and resuspended with 100 µl of PBT. Plates were read using a Luminex® MAGPIX® system and the median  
158 fluorescence intensity (MFI) was retained for analysis. To obtain a kinetic curve of the RBD-ACE2 binding  
159 inhibition for an individual sample, 7 points-2-fold serum dilution from 1/10 to 1/640 and one reference control  
160 point (without serum) were prepared in advance. The ACE2-RBD binding inhibition has been measured  
161 indirectly, as the MFI corresponds to fluorescence emitted by Streptavidin-phycoerythrin bound to biotinylated  
162 ACE2 antigen complex. Therefore, the MFI reading is inversely proportional to the concentration of neutralizing  
163 antibodies present in the serum.

164

165 *S-Fuse neutralization assay*

166 U2OS-ACE2 GFP1–10 or GFP 11 cells, also termed S-Fuse cells, become GFP+ cells when they are  
167 productively infected with SARS-CoV-2. Cells tested negative for mycoplasma. Cells were mixed (at a 1:1  
168 ratio) and plated at  $8 \times 10^3$  cells per well in a  $\mu$ Clear 96-well plate (Greiner Bio-One). The indicated SARS-  
169 CoV-2 strains were incubated with sera at the indicated concentrations or dilutions for 15 min at room  
170 temperature and added to S-Fuse cells. The sera were heat inactivated for 30 min at 56 °C before use. Then,  
171 18 hours later, cells were fixed with 2% paraformaldehyde, washed and stained with Hoechst (1:1,000 dilution;  
172 Invitrogen). Images were acquired with an Opera Phenix high-content confocal microscope (PerkinElmer). The  
173 GFP area and the number of nuclei were quantified using the Harmony software (PerkinElmer). The percentage  
174 of neutralization was calculated using the number of syncytia as the value with the following formula:

175 
$$\left(1 - \frac{\text{value "with serum"} - \text{value "non infected"}}{\text{value "no serum"} - \text{value "non infected"}}\right) * 100$$

176 The neutralizing activity of each serum was expressed as the ED50 (reported in dilution units), which was  
177 calculated using a reconstructed curve based on the percentage of neutralization at different concentrations. An  
178 ED50 threshold of 30 has been defined below which sera samples have no neutralizing activity<sup>18</sup>.

179 *Data analysis*

180 The ACE2-RBD binding inhibition was calculated for all 13 antigenic targets as a percentage of ACE2  
181 maximum binding by dividing the MFI obtained for an individual serum by the MFI of the well without serum  
182 (only with ACE2, reference MFI), with the following calculation:

183 
$$100 - \frac{100 * MFI}{referenceMFI}$$

184 A threshold for positivity was established based on the analysis obtained with negative controls. We defined a  
185 threshold of 20% ACE2-RBD binding inhibition below which samples do not have neutralizing antibodies and  
186 are considered negative.

187 Microsoft Excel 2016 and R version 4.0.5. RStudio was used to run the analysis, with dplyr, readxl, tidy,  
188 ggplot2, openxlsx and stringr packages.

189 *Ethical approval*

190 Collection of samples from the Orleans cohort had been approved by the Comité de Protection des Personnes  
191 Ile de France IV (NCT04750720). The study of the COVID-Oise cohort was registered with ClinicalTrials.gov  
192 (NCT04644159) and received ethical approval by the Comité de Protection des Personnes Nord Ouest IV.  
193 Several COVID-Oise participants participated in the CORSER studies in spring 2020, registered with  
194 ClinicalTrials.gov (NCT04325646) and approved by the Comité de Protection des Personnes Ile de France III.  
195 For all studies, participants did not receive any compensation. Informed consent was obtained from all



196 participants, and parents provided informed consent for any children under the age of 18 years. For the nursing  
197 home residents who did not have full capacity to sign legal documents, informed consent was obtained from  
198 their relatives.

199


## 200 **Results**

### 201 *Diversity of ACE2-RBD binding inhibition profiles after infection and/or vaccination*

202 To validate the assay, we measured the dose response curves from five samples with differing immunological  
203 profiles according to infection and vaccination status. Five different characterized serum samples were tested,  
204 including a pre-pandemic negative pool, a positive pool of individuals infected at the beginning of the pandemic,  
205 two samples from individuals vaccinated with one or two doses respectively, as well as a sample from an  
206 infected and vaccinated (1 dose) individual.

207

208



209

210 *Figure 1: Inhibition profiles of SARS-CoV-2 RBD-ACE2 binding for five representative samples of differing status*  
211 *(uninfected, infected and/or vaccinated). A bead-based multiplex assay using three characterized vaccinated serum*  
212 *samples: 1 dose (green), 2 doses (blue) and 1 dose plus SARS-CoV-2 infection (pink) was used. A positive pool of plasma*  
213 *from infected individuals (yellow) and a negative pre-pandemic pool (red) was used. Results are shown for WT Spike and*  
214 *RBD antigens, as well as RBD antigens of SARS-CoV-2 variants Alpha, Beta, Gamma, Kappa, Delta and Omicron (lineage*  
215 *BA.1). A 7-point 2-fold titration was performed for all samples. The plots show the percentage of RBD-ACE2 inhibition*  
216 *according to serum dilution. The horizontal dotted line represents the threshold of the assay.*

217 At the lowest serum dilution the percentage of inhibition of the ACE2-RBD binding is zero for the negative pre-  
218 pandemic pool (Fig. 1). The ACE2-RBD binding inhibition increase over 45% for RBD WT after one single  
219 dose of vaccine. A higher ACE2-RBD binding inhibition is observed for the double vaccinated individual  
220 sample compared to the positive pool, with an inhibition percentage of 90% and 70% respectively. We note that  
221 for these last four samples the percentage of inhibition of ACE2-RBD binding decreases for most VOCs,  
222 especially for Omicron. For the vaccinated plus infected individual (hybrid immunity), we observed an ACE2-  
223 RBD binding inhibition around 100%, not only for the ancestral form but also for the VOCs (except for Beta  
224 and Omicron variant for which the maximum value is below 90% inhibition). The large inter-individual  
225 variation observed for these five representative samples, due to their different serological status, enabled us to  
226 validate the test.

### 227 Association between ACE2-RBD binding inhibition, live virus neutralization and IgG antibody levels

228 We investigated the association between the ACE2-RBD binding inhibition data from our surrogate virus  
229 neutralization test and the ED50 data from the live virus neutralization assay. We have defined a threshold of  
230 20% ACE2-RBD binding inhibition for our assay and an ED50 threshold of 30. Values below these thresholds  
231 indicate that antibodies present in the serum are unable to inhibit the binding, therefore the serum has limited  
232 neutralizing effect. We observe strong association between the ED50 value and ACE2-RBD binding inhibition,  
233 especially for RBD WT, Alpha, Beta and Delta variants ( $R^2$  between 0.68 and 0.73). When we restrict to samples  
234 with measured neutralization activity ( $ED50 > 30$ ), we observe a linear association and noticeably stronger  
235 correlation between 0.66, and 0.79 (Fig. 2 panel A). The strong correlation between both assays allows us to  
236 validate our surrogate virus neutralization assay, which aims to estimate the capacity of antibodies present in  
237 the serum to inhibit the ACE2-RBD binding and thus prevent virus entry.


238 Subsequently, we study if there was a correlation between IgG antibody levels (MFI) and the ACE2-RBD  
239 binding inhibition. For this purpose, we used a multiplex serology test to measure IgG levels and compared to  
240 the ACE2-RBD binding inhibition data. The correlation between IgG antibody levels and their neutralizing  
241 capacities is non-linear (Fig. 2, panel B). For ACE2-RBD binding inhibition  $>20\%$  we observe an approximately  
242 linear relationship, with correlation coefficients in the range 0.71 – 0.79, with the exception of Omicron which  
243 had a lower correlation of 0.21 owing to lower levels of binding inhibition.

244

245

246





247


248 *Figure 2: A) Association between ACE2-RBD binding inhibition and EC50 live virus neutralization. B) Association*  
 249 *between ACE2-RBD binding inhibition and IgG antibody levels. Samples from vaccinated and/or infected individuals were*  
 250 *used (n=412). Results are shown for WT RBD and VOC RBDs. The horizontal dotted lines on panel A and B correspond*  
 251 *to our in-house assay threshold. The vertical dotted lines on panel A correspond to the live virus neutralization assay*  
 252 *threshold.*

253 *Neutralizing antibody levels in individuals followed one-year post-vaccination*

254 A cohort of vaccinated individuals was followed with samples collected from week 2 after the first dose and  
 255 continued until 6 months after the second dose.

256 In samples taken from individuals just after administration of the first vaccine dose, negligible binding inhibition  
 257 and ED50 neutralization value (Fig. 3) was observed. The ED50 value and the binding inhibition increases  
 258 considerably for all variants after second dose, especially WT RBD, Delta RBD and Alpha RBD, with a binding  
 259 inhibition of 49.1%, 41% and 36.1% respectively. It is worth noting that for the live virus neutralization results,  
 260 a higher titer of neutralizing antibodies is directed towards Alpha RBD and subsequently to WT RBD and Delta  
 261 RBD. This confirms that the neutralizing antibodies produced after vaccination cross-react with several variants  
 262 of the virus.


263 As described previously, COVID-19 vaccines are not equally effective against all variants<sup>16</sup>. Following a third  
264 dose, a higher antibody neutralizing capacity is noticeable for RBD WT, Alpha, and Delta with a median ACE2-  
265 RBD binding inhibition of 57.5%, 56.5% and 44.9% respectively. Followed by a significant decrease for the  
266 latest VOC: Omicron, with a median of 23.7%, consistent with lower vaccine efficacy. Similar results are  
267 observed for the live virus neutralization assay, an increase in the ED50 value is observed after the booster dose,  
268 suggesting that vaccination induces the production of neutralizing antibodies against several variants, especially  
269 against RBD WT and Alpha. On the contrary, for the vaccination regimens considered, the median  
270 neutralization activity for the SARS-CoV-2 Omicron variant is under the thresholds of ED50 = 30, suggesting  
271 that there are limited levels of anti-RBD Omicron neutralizing antibodies present in the serum.  
272



273  
274 *Figure 3: ACE2-RBD binding inhibition and ED50 neutralization according to the number of Pfizer/BioNTech BNT162b2*  
275 *vaccine doses. Samples from 11 individuals were collected three weeks after each dose of vaccine (n=36). Results from*  
276 *WT RBD and VOC RBDs are shown. On top are shown the results obtained with the multiplex surrogate virus*  
277 *neutralization test and on the bottom live virus neutralization assay. The dotted lines correspond to the respective*  
278 *thresholds.*

279 The kinetics of neutralizing antibodies and ACE2-RBD binding inhibition followed similar patterns over time.  
280 A peak of neutralizing antibody titers and ACE2-RBD binding inhibition appears around week 4 and week 36

281 post vaccination, corresponding to 4 weeks after the first dose and booster dose respectively (Fig. 4). This  
282 representation showed a rapid decline of the ACE2-RBD binding inhibition over 20 weeks. Similarly, a decrease  
283 in the ED50 value after week 6 is observed for the live virus neutralization assay, however this decrease in  
284 neutralizing antibodies is not as pronounced. Moreover, anti-RBD neutralizing antibodies decreases  
285 considerably four and a half months after second vaccine dose, suggesting that COVID-19 vaccination will  
286 probably have short-lasting protective effect.  
287



288 *Figure 4: Kinetics of ACE2-RBD binding inhibition and neutralization titer overtime following Pfizer/BioNTech BNT162b2*  
289 *vaccination. Samples from 11 individuals were collected frequently after their first dose. On the left the results obtained*  
290 *with the surrogate virus neutralization assay and on the right live virus neutralization assay. Results are shown for RBD*  
291 *WT antigen. The dotted lines correspond to the respective thresholds.*  
292

### 293 Protection estimates

294 The SARS-CoV-2 surrogate live virus neutralization assay enables us to assess protection estimates against  
295 breakthrough infection in large population studies. This assay was applied to samples from a longitudinal French  
296 cohort study from the town of Crépy-en-Valois (Covid-Oise study), where sera samples were collected from  
297 approximately 515 individuals in December 2021 (Session 3) and April 2022 (Session 4). During this time, the  
298 Omicron (lineages BA.1 and BA.2) wave swept through France, infecting large numbers of individuals. Most  
299 individuals had received between 1 and 2 doses of vaccine.

300 By measuring anti-N IgG responses, we identified individuals who were infected before Session 3 or Session  
301 4. Moreover, our analysis enabled the identification of individuals who experienced reinfection between the two  
302 sampling periods, by detecting individuals who exhibited a four-fold increase in anti-N antibody levels (Table  
303 1). This analysis allows the categorization of individuals into five subgroups based on their serostatus, each  
304 denoted by a short name in Table 1 and Fig. 5. Individuals who tested negative at Session 3 and Session 4 are

305 classified as “neg\_neg”. Those who were negative in Session 3 but positive in Session 4 are termed “neg\_pos”.  
 306 Individuals who tested positive at Session 3 but subsequently sero-reverted to negative by Session 4 are  
 307 classified as “pos\_neg”. Those who tested positive at both sessions without evidence of new infection between  
 308 the two cross-sections are labeled as “pos\_pos”. Lastly, individuals who tested positive at Session 3 and were  
 309 identified as being reinfected between the two sessions are designated as “pos\_boost”. In this subgroup, the  
 310 significant rise of the median anti-N antibodies levels from 28 to 840 (expressed in x10<sup>-5</sup>) between the two  
 311 sessions strongly indicates a re-infection event.


categories		neg_neg	pos_neg	pos_pos	neg_pos	pos_boost
count n (%)		94 (18.3 %)	22 (4.3 %)	198 (38.4 %)	107 (20.8 %)	94 (18.3 %)
anti-NP IgG median * [IQR] *expressed in x10 <sup>-5</sup>	Session 3	5.8 [4.6;7.4]	13[12;18]	65 [32;150]	5.7 [4.2;7.6]	28 [15;64]
	Session 4	5.3 [4.2;6.9]	7.2 [5.4;8.4]	37 [20;72]	82 [32; 210]	840 [250;2500]
ACE2-RBD binding inhibition median at Session 3 [IQR]	Wuhan strain	26.8% [12.7;47.4]	45.7% [32.6;65.4]	71.4% [31.5;90.4]	24.5% [12.9;41.3]	57.2% [22.3;83.3]
	Omicron strain	14.3% [8.5;18.2]	19% [14.2;21.9]	24.1% [13.7;41.2]	14.7% [9.8;20]	17.8% [11.9;30.1]
age [min;max]		50 [9;93]	52 [17;80]	52 [9;98]	39 [6;85]	41 [7;94]
female count n (%)		58 (61.7%)	17 (77.3%)	128 (64.6%)	64 (59.8%)	70 (74.5%)
Vaccination status count n (%)	unvaccinated	7 (7.4%)	1 (4.5%)	22 (11.1%)	19 (17.8%)	17 (18.1%)
	one dose	8 (8.5%)	9 (40.9%)	95 (48%)	10 (9.3%)	43 (45.7%)
	two doses	71 (75.5%)	12 (54.5%)	58 (29.3%)	72 (67.3%)	29 (30.9%)
	three doses	7 (7.4%)	0 (0%)	23 (11.6%)	5 (4.7%)	5 (5.3%)
	unknown	1 (1.1%)	0 (0%)	0 (0%)	1 (0.9%)	0 (0%)

312 *Table 1: Overview of the five different serostatus subgroups within the sample set, including the number and percentage*  
 313 *of individuals in each subgroup. The median and interquartile range of anti-N antibody levels for sessions 3 and 4, are*  
 314 *expressed in RAU. The median and interquartile range of ACE2-RBD binding inhibition for Wuhan and Omicron strains*  
 315 *measured at Session 3 are detailed. The median age, number of females, and vaccination status (number of vaccine doses)*  
 316 *are also provided for each subgroup.*

317  
 318 We investigated correlates of protection by analyzing ACE2-RBD WT and Omicron binding inhibition  
 319 measurements obtained at Session 3 along with the serostatus defined at both Sessions (Fig. 5). The first key  
 320 comparison was between groups with no evidence of infection before Session 3 (anti-N IgG sero-negative).  
 321 Both the “neg\_neg” and “neg\_pos” groups had high levels of ACE2-RBD WT binding inhibition, consistent  
 322 with high levels of vaccine-induced immunity. There was no significant difference in ACE2-RBD WT binding  
 323 inhibition between these groups (P value = XX; wilcoxon test), consistent with the hypothesis that ACE2-RBD  
 324 WT binding inhibition is not associated with protection from infection with the SARS-CoV-2 Omicron Variant  
 325 in vaccinated individuals. Furthermore, all individuals who were uninfected before Session 3 had very low  
 326 levels of ACE2-RBD Omicron binding inhibition, so it was not possible to detect significant associations  
 327 between Omicron specific humoral immune responses and protection from infection.

328  
 329 The second key comparison is between groups with evidence of infection before Session 3 (anti-N IgG sero-  
 330 positive). Both the “pos\_pos” and “pos\_boost” groups had high levels of ACE2-RBD WT binding inhibition.

331 The “pos\_pos” group had significantly higher ACE2-RBD WT binding inhibition than the “pos\_boost” group  
 332 (P value = 0.008), consistent with the hypothesis that in individuals with hybrid immunity, greater ACE2-RBD  
 333 WT binding inhibition is associated with protection from infection. Although Omicron specific ACE2-RBD  
 334 binding inhibition levels were substantially lower, we still observed a significant association between ACE2-  
 335 RBD Omicron binding inhibition and protection from infection (P value = 0.001). These results indicate that  
 336 RBD Omicron binding inhibition is not associated with protection against Omicron infection in individuals who  
 337 have acquired immunity solely through vaccination. However, for individuals with hybrid immunity (due to  
 338 both vaccination and previous infection), higher RBD Omicron binding inhibition is associated with increased  
 339 protection against an Omicron infection.



340

341 *Figure 5: Panel A) Levels of anti-N IgG from Covid-Oise cohort Session 3 (December 2021) and Session 4 (April 2022)*  
 342 *are illustrated for each individual, ensuring matched comparisons between sessions. Each category is consistently color-*  
 343 *coded across the different panels in accordance with the descriptions provided previously. In light blue are individuals,*  
 344 *who were negative in Session 3 and Session 4 (“neg\_neg”). In red are individuals negative in Session 3 and positive in*  
 345 *Session 4 (“neg\_pos”). In green are individuals who were positive at both sessions, but without evidence of new infection*  
 346 *between the two cross-sections (“pos\_pos”). In yellow are individuals positive at Session 3 and identified as being*  
 347 *reinfected between the two cross-sections. In dark blue are individuals who were positive at Session 3 but then sero-*  
 348 *reverted to negative at Session 4. The horizontal and vertical red lines represent the threshold for seropositivity. Panel B)*  
 349 *The ACE2-RBD binding inhibition for the WT variant at Session 3 among the previously presented subgroups. The red*  
 350 *horizontal dotted line represents the threshold of our assay. Panel C) The ACE2-RBD binding inhibition for the Omicron*  
 351 *variant at Session 3 among the previously described subgroups. The red horizontal dotted line represents the threshold of*  
 352 *our assay.*

353

354

355

356

## 357 Discussion

358 To investigate the neutralizing capacity of antibodies against SARS-CoV-2 variants, we developed a multiplex  
359 surrogate virus neutralization test based on ACE2-RBD binding inhibition. This allowed us to develop an  
360 accurate and rapid high-throughput multiplex test that could adapt easily as numerous SARS-CoV-2 variants  
361 emerged. Additionally, our test overcomes the main disadvantages of conventional virus neutralization assay,  
362 since no virus, no live cells, no large volume of sera and limited biosafety requirements are needed. The analysis  
363 of well-characterized sera samples from infected and/or vaccinated subjects showed a strong correlation  
364 between the surrogate virus neutralization test and the gold standard live virus neutralization assay.

365 We studied vaccinated individuals to gain deeper insights into antibody kinetics following vaccination. Prior  
366 research has suggested a characteristic pattern in antibody levels: a peak three weeks after infection or  
367 vaccination is observed, followed by a rapid decline in subsequent months, and then a slower decrease eight  
368 months post immunization<sup>19-21</sup>. Our findings align with this pattern, revealing that both binding and neutralizing  
369 antibodies follows a similar kinetic post-vaccination. This suggests that the neutralizing capacity of antibodies  
370 is closely correlated with antibody levels and their maturation. Notably, a third vaccine dose was associated  
371 with significantly higher ACE2-RBD binding inhibition compared to two doses, indicating that a booster dose  
372 enhances protection against all VOCs. This suggests that COVID-19 vaccination may confer short-lasting  
373 protective effects, necessitating additional booster doses for certain population groups as elderly or  
374 immunocompromised individuals<sup>22,23</sup>.

375 Additionally, our study provides valuable insights into the neutralizing antibody response to various SARS-  
376 CoV-2 variants and its role in providing protection against Omicron breakthrough infections within the  
377 vaccinated population. We noted among vaccinated individuals, that the ACE2-RBD binding inhibition against  
378 RBD variants, especially Omicron, is reduced compared to the ancestral virus. As described in the literature,  
379 the accumulation of mutations within the Omicron variant has an impact on the binding affinity to ACE2, which  
380 gives a greater chance to evade host immunity, enhancing transmissibility<sup>24</sup>. Studies have shown that mutations  
381 on Omicron RBD result in stronger binding to ACE2, therefore antibodies elicited by vaccine-acquire immunity  
382 showed reduced ACE2-RBD binding inhibition and neutralization potential<sup>25</sup>. Indeed, RBD is responsible for  
383 the attachment to ACE2 human cell receptor, thus high avidity and neutralizing anti-RBD antibodies plays an  
384 essential part in the prevention of infection by blocking this interaction.

385 In our study, samples from a longitudinal population cohort collected in December 2021 and April 2022, were  
386 used to measure immunity to breakthrough SARS-CoV-2 infection. Results shown that the ACE2-RBD binding  
387 inhibition from individuals infected prior to Session 3 and re-infected between both Sessions (probably with the  
388 Omicron variant), showed lower levels of neutralizing antibodies compared to individuals infected prior to  
389 Session 3 and without any sign of a new infection. These individuals who experienced reinfection were likely  
390 more susceptible due to the fact that their levels of neutralizing antibodies were lower at Session 3 (52.7% and  
391 17.8% for Wuhan and Omicron variant respectively). Suggesting that two doses of the vaccine may not provide  
392 adequate protection against the Omicron variant for some individuals, underscoring the importance of  
393 implementing booster doses. This is particularly crucial as we observed breakthrough infections occurring  
394 despite initial infection. However, our study also indicates that individuals with high levels of antibodies from  
395 hybrid immunization, such as those induced by previous infection and subsequent vaccination, demonstrate  
396 enhanced protection against emerging variants like Omicron. This underscores the importance of continually  
397 assessing the evolution of SARS-CoV-2 and its variants, along with evaluating the effectiveness of vaccine  
398 induced anti-RBD antibodies against diverse strains. Such efforts are essential for better understanding the  
399 protective immune response.

400 While our assay provided valuable insights, it is crucial to acknowledge its limitations, as it only allows us to  
401 measure the MFI of the Streptavidin phycoerythrin bound to the biotinylated ACE2 receptor. We do not directly



402 read the MFI of antibodies bound to the antigens coupled beads. Consequently, the isotype of the neutralizing  
403 antibodies in the serum is unknown. Several studies demonstrated that specific mucosal IgA antibodies have a  
404 crucial role in early virus neutralization<sup>26</sup>. This is a notable limit of our study as we only optimized and  
405 performed this test on serum samples, since we intended to have a global view of neutralizing antibody levels  
406 and the protection given by vaccination. It could be contemplated in the future to conduct our assay using  
407 nasopharyngeal or saliva samples, in the cases of infection acquired immunity. It is important to note that these  
408 experiments have been done with a limited sample diversity, as the major global vaccination campaign, made  
409 it difficult to do serological follow-ups on unvaccinated individuals infected by new SARS-CoV-2 variants.

#### 410 **Conclusion**

411 The development of this multiplex surrogate virus neutralization test based on ACE2-RBD binding provides  
412 accurate information on neutralizing antibodies levels that can allow us to better understand the kinetics, their  
413 functionality and the protection provided at population level. Therefore, we can apply this high-throughput tool  
414 to SARS-CoV-2 emerging variants to estimate functional protection conferred by vaccination or infection. This  
415 assay enables us to assess clinical protection against SARS-CoV-2 variants and evaluate the effectiveness of  
416 vaccines or antibody therapeutics, providing essential information to monitor the pandemic's evolution.

417

#### 418 **Author contributions**

419 EB developed the assay, analysed samples, and wrote the first draft of the manuscript. EB and MW analysed  
420 the data. LG, FD, SP and JR supported assay development. DP and TB performed the neutralization assay. AF,  
421 LP and OS provided access to samples. MW designed the study.

#### 422 **Acknowledgements**

423 The authors thank the participants who agreed to participate into the different studies and the medical and  
424 paramedical teams who were involved in sample and data collection. They thank the teams of Crépy-en-Valois  
425 town hall and the director and technical services of the local hospital for their help in implementing the COVID-  
426 Oise study. They also thank the Institut Pasteur's Investigation Clinique et Accès aux Ressources Biologiques  
427 team for sample management and Institut Pasteur's Pôle de Coordination de la Recherche Clinique for support  
428 with regulatory processes.

429 **Data availability** All data produced in the present study are available on request to the authors.

430 **Competing interests** All authors report that they have no conflicts of interest.

431 **Funding** This work was supported by the European Research Council (MultiSeroSurv 852373 to M. W.); the  
432 French government's "Integrative Biology of Emerging Infectious Diseases" (Investissement d'Avenir grant  
433 ANR-10-LABX-62-IBEID) and INCEPTION programs (Investissement d'Avenir grant ANR-16-CONV-  
434 0005). The COVID-Oise cohort is funded by Alliance Tous Unis Contre le Virus, Institut Pasteur, AP-HP, and  
435 Fondation de France.

436

437

438

439

440

441

## 442 **References**

- 443 1. Gorkhali, R. et al. Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. *Bioinforma.*  
444 *Biol. Insights* 15, 11779322211025876 (2021).
- 445 2. V'kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication:  
446 implications for SARS-CoV-2. *Nat. Rev. Microbiol.* 19, 155–170 (2021).
- 447 3. Scialo, F. et al. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. *Lung* 198, 867–877 (2020).
- 448 4. Min, L. & Sun, Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. *Front. Mol. Biosci.* 8, (2021).
- 449 5. Marot, S. et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare  
450 workers. *Nat. Commun.* 12, 844 (2021).
- 451 6. Burton, D. R., Williamson, R. A. & Parren, P. W. H. I. Antibody and Virus: Binding and Neutralization.  
452 *Virology* 270, 1–3 (2000).
- 453 7. Piccoli, L. et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-  
454 Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 183, 1024-1042.e21 (2020).
- 455 8. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from  
456 symptomatic SARS-CoV-2 infection. *Nat. Med.* 27, 1205–1211 (2021).
- 457 9. Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 39,  
458 4423–4428 (2021).
- 459 10. Cosar, B. et al. SARS-CoV-2 Mutations and their Viral Variants. *Cytokine Growth Factor Rev.* 63, 10–22  
460 (2022).
- 461 11. Lopez, E. et al. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex  
462 assay. *JCI Insight* 6, (2021).
- 463 12. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage  
464 of ACE2-spike protein-protein interaction. *Nat. Biotechnol.* 38, 1073–1078 (2020).
- 465 13. Woudenberg, T. et al. Estimated protection against COVID-19 based on predicted neutralisation titres  
466 from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.  
467 *Eurosurveillance* 28, 2200681 (2023).
- 468 14. Fontanet, A. et al. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological  
469 cohort study in an area of high transmission, France, January to April 2020. *Eurosurveillance* 26, 2001695  
470 (2021).
- 471 15. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* 602,  
472 671–675 (2022).
- 473 16. Woudenberg, T. et al. Humoral Immunity to SARS-CoV-2 and Inferred Protection from Infection in a  
474 French Longitudinal Community Cohort. (2022).
- 475 17. Rosado, J. et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2  
476 infection: an antibody-based diagnostic and machine learning study. *Lancet Microbe* 2, e60–e69 (2021).
- 477 18. Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients

- 478 receiving monoclonal antibodies. *Nat. Med.* (2022) doi:10.1038/s41591-022-01792-5.
- 479 19. Bates, T. A. et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated  
480 serum. *Nat. Commun.* 12, 5135 (2021).
- 481 20. Reifer, J., Hayum, N., Heszel, B., Klagsbald, I. & Streva, V. A. SARS-CoV-2 IgG antibody responses in  
482 New York City. *Diagn. Microbiol. Infect. Dis.* 98, 115128 (2020).
- 483 21. Pelleau, S. et al. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response  
484 and Serological Estimation of Time Since Infection. *J. Infect. Dis.* 224, 1489–1499 (2021).
- 485 22. Levin Einav G. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6  
486 Months. *N. Engl. J. Med.* 385, e84 (2021).
- 487 23. Samanovic, M. I. et al. Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity:  
488 A Comparison of Three COVID-19 Vaccines. *Vaccines* 10, 2152 (2022).
- 489 24. Chen, L.-L. et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-  
490 Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies  
491 Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. *Clin. Infect. Dis.* 74, 1623–  
492 1630 (2022).
- 493 25. Lupala, C. S., Ye, Y., Chen, H., Su, X.-D. & Liu, H. Mutations on RBD of SARS-CoV-2 Omicron variant  
494 result in stronger binding to human ACE2 receptor. *Biochem. Biophys. Res. Commun.* 590, 34–41  
495 (2022).
- 496 26. Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci. Transl.*  
497 *Med.* 13, eabd2223 (2021).